文献速递神经免疫

为进展型多发性硬化神经保护设计多臂多阶段自适应试验

Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
PubMed 文献 · Neurology · 2022-03-23

针对进展型多发性硬化缺乏延缓残疾进展的疗法,本文提出多臂多阶段(MAMS)平台试验设计,通过两个阶段评估3个试验组与1个共同标准治疗组,第一阶段以18个月全脑萎缩为终点、每组123人,第二阶段以6个月确认残疾进展时间为终点、每组600人,预计招募约1900人、历时约6年,约为分开的两臂II期和III期试验规模的三分之二、时间的一半。

要点

  • MAMS设计分两阶段:第一阶段以18个月MRI全脑萎缩筛选治疗,每组123人。
  • 第二阶段最终终点为6个月确认残疾进展时间,检测HR 0.75需每组600人、90%效能。
  • 预计招募约1900人、历时约6年,约为分开两臂试验规模的三分之二、时间的一半。

核心结论

  • 所提出的MAMS试验设计相比传统临床试验可大幅缩短时长和减少样本量,加速发现进展型多发性硬化的有效治疗。
  • 该设计受到多发性硬化患者好评。
  • MAMS设计的实用和统计学原则可能适用于其他神经退行性疾病,以促进新疗法的高效测试。

研究设计与样本

  • 英国多发性硬化协会进展型多发性硬化临床试验专家联盟回顾了近期II期和III期进展型多发性硬化试验,以指导中期和最终结局选择及设计指标。
  • 进行了模拟以评估不同治疗效果、招募速度和样本量假设下的试验操作特征。
  • 多发性硬化患者组成患者和公众参与小组,参与试验设计,确保满足多发性硬化群体的需求。
  • proposed design evaluates 3 experimental arms compared to a common standard of care arm in 2 stages.

主要发现

  • 第一阶段(中期)结局为18个月时MRI全脑萎缩,每组评估123名参与者。
  • 有足够证据表明减缓脑萎缩的治疗将继续进入第二阶段。
  • 第二阶段(最终)结局为6个月确认残疾进展时间,基于包含扩展残疾状态量表、定时25英尺步行测试和9孔钉测试的复合临床评分。
  • 为检测最终主要结局的风险比0.75,以90%效能,每组需要600名参与者。
  • 假设一种治疗进入第二阶段,试验将招募约1900名参与者,持续约6年。

关键数值与推荐

  • 第一阶段(中期)结局:18个月时MRI全脑萎缩,每组123名参与者评估。
  • 第二阶段(最终)结局:6个月确认残疾进展时间,基于扩展残疾状态量表、定时25英尺步行测试和9孔钉测试的复合临床评分。
  • 检测最终主要结局的风险比0.75,以90%效能,每组需要600名参与者。
  • 假设一种治疗进入第二阶段,试验将招募约1900名参与者,持续约6年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are few treatments shown to slow disability progression in progressive multiple sclerosis (PMS). One challenge has been efficiently testing the pipeline of candidate therapies from preclinical studies in clinical trials. Multi-arm multistage (MAMS) platform trials may accelerate evaluation of new therapies compared to traditional sequential clinical trials. We describe a MAMS design in PMS focusing on selection of interim and final outcome measures, sample size, and statistical considerations. The UK MS Society Expert Consortium for Progression in MS Clinical Trials reviewed recent phase II and III PMS trials to inform interim and final outcome selection and design measures. Simulations were performed to evaluate trial operating characteristics under different treatment effect, recruitment rate, and sample size assumptions. People with MS formed a patient and public involvement group and contributed to the trial design, ensuring it would meet the needs of the MS community. The proposed design evaluates 3 experimental arms compared to a common standard of care arm in 2 stages. Stage 1 (interim) outcome will be whole brain atrophy on MRI at 18 months, assessed for 123 participants per arm. Treatments with sufficient evidence for slowing brain atrophy will continue to the second stage. The stage 2 (final) outcome will be time to 6-month confirmed disability progression, based on a composite clinical score comprising the Expanded Disability Status Scale, Timed 25-Foot Walk test, and 9-Hole Peg Test. To detect a hazard ratio of 0.75 for this primary final outcome with 90% power, 600 participants per arm are required. Assuming one treatment progresses to stage 2, the trial will recruit ≈1,900 participants and last ≈6 years. This is approximately two-thirds the size and half the time of separate 2-arm phase II and III trials. The proposed MAMS trial design will substantially reduce duration and sample size compared to traditional clinical trials, accelerating discovery of effective treatments for PMS. The design was well-received by people with multiple sclerosis. The practical and statistical principles of MAMS trial design may be applicable to other neurodegenerative conditions to facilitate efficient testing of new therapies.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Li V, Leurent B, Barkhof F, et al. Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis. Neurology. 2022. PMID: 35321926. doi:10.1212/WNL.0000000000200604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。